FDA Investigators Clarify Issues With Draft Inspection Guidance

FDA draft guidance on what constitutes delaying or denying an inspection continues to leave drugmakers concerned about how to interact with agency investigators on issues such as photos and records retrieval.
Washington Drug Letter